These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9071897)

  • 1. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
    Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
    Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T; Shousha S
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
    Ottesen GL; Christensen IJ; Larsen JK; Larsen J; Baldetorp B; Linden T; Hansen B; Andersen J
    Breast Cancer Res Treat; 2000 Apr; 60(3):219-26. PubMed ID: 10930109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
    Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
    Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
    Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
    Frolik D; Caduff R; Varga Z
    Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of interleukin-1beta in human breast carcinoma.
    Jin L; Yuan RQ; Fuchs A; Yao Y; Joseph A; Schwall R; Schnitt SJ; Guida A; Hastings HM; Andres J; Turkel G; Polverini PJ; Goldberg ID; Rosen EM
    Cancer; 1997 Aug; 80(3):421-34. PubMed ID: 9241076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
    Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
    Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
    Radhi JM
    Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L; Kerkvliet N; Doig G; O'Malley FP
    Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma.
    Turunen N; Karihtala P; Mantyniemi A; Sormunen R; Holmgren A; Kinnula VL; Soini Y
    APMIS; 2004 Feb; 112(2):123-32. PubMed ID: 15056229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.